GSK-971086
 | |
| Clinical data | |
|---|---|
| Drug class | Selective androgen receptor modulator |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| UNII | |
| Chemical and physical data | |
| Formula | C21H12F6N4O |
| Molar mass | 450.344 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
GSK-971086 is an investigational new drug that is a selective androgen receptor modulator (SARM) that was being developed by GlaxoSmithKline (GSK) for the potential treatment of sarcopenia.[1][2] As a SARM, GSK-971086 was designed to target androgen receptors in specific tissues, potentially offering therapeutic benefits for muscle wasting conditions while minimizing unwanted androgenic side effects. The compound underwent early-stage clinical trials to evaluate its safety, tolerability, and pharmacokinetic profile in human subjects.[3]
References
[edit]- ^ "GSK 971086". AdisInsight. Springer Nature Switzerland AG. Archived from the original on 2024-01-14. Retrieved 2024-01-14.
- ^ Fonseca GW, Dworatzek E, Ebner N, Von Haehling S (August 2020). "Selective androgen receptor modulators (SARMs) as pharmacological treatment for muscle wasting in ongoing clinical trials". Expert Opinion on Investigational Drugs. 29 (8): 881–891. doi:10.1080/13543784.2020.1777275. PMID 32476495.
- ^ "Study to Test Safety, Tolerability and Blood Levels of GSK971086 after 1 Dose & 7 Days of Dosing in Healthy Adult Males". GSK Study Register. SAR109935.
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |